Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Important safety information on Dolutegravir in Namibia |
10/10/2018 |
 |
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck | 15/02/2024 | |
| Important safety information on Varilrix in Namibia (November 2020) | 4/11/2020 | |
| Important safety information on Varilrix in Namibia (January 2021) | 21/01/2021 | |
| Important safety information on Cephalosporins in Namibia (Safety Notification_Cephalosporins and risk of seizure) | 01/03/2023 | |
Important safety information on Cephalosporins in Namibia (Safety Notification_Cephalosporins and risk of neurotoxicity) |
07/03/2023 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Namibia |
09/09/2023 | |
| Important safety information on Dolutegravir containing products in Namibia (Safety Notification_Korean label update for Dolutegravir containing products) | 02-11-2023 | |
Important safety information on Amoxicillin/clavulanic acid containing products - MedSafe communication regarding labelling updates |
19/12/2023 |
|
Important safety information on Zanamivir containing products - Precautions for prescribing and administering flu medications (zanamivir) |
26/12/2023 |
|
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain Paroxetine |
27/12/2023 |
|
Important safety information on Abacavir containing products - Regarding amendments to the instructions for medical use of medicines containing abacavir |
19/03/2024 |
|
Important safety information on Acyclovir containing products - ACYCLOVIR/VALACYCLOVIR – RISK OF DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) |
17/04/2024 |
|
